Anti-Inflammatory gene therapy for cardiovascular disease

Current Gene Therapy

Volumn 11, Issue 6, 2011, Pages 442-446

  Matoba, Tetsuya ^a   Egashira, Kensuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Artherosclerosis; Gene delivery system; Gene expression assays. gene therapy; Neointima

Indexed keywords

AMINO TERMINAL 7 AMINO ACID; ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CCR2; HETERODIMER; MONOCYTE CHEMOTACTIC PROTEIN 1; NANOPARTICLE; PLASMID DNA; POLYMER; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BARE METAL STENT; BIOCOMPATIBILITY; CARDIOVASCULAR GENE THERAPY; CELL INFILTRATION; CHEMOTAXIS; FEMORAL ARTERY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; ILIAC ARTERY; KINETICS; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MONOCYTE; NANOENCAPSULATION; NEOINTIMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; PERITONEUM MACROPHAGE; PROTEIN BINDING;

ANIMALS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INFLAMMATION; MICE; NEOINTIMA; RABBITS; RECEPTORS, CCR2; STENTS;

EID: 82055161738     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311798192888     Document Type: Article

References (18)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Gu L, Okada Y, Clinton S, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998; 2: 275-81.
3. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in ccr2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-7.
4. Zhang Y, Rollins BJ. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. Mol Cell Biol 1995; 15: 4851-5.
5. Ni W, Egashira K, Kitamoto S, Kataoka C. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in. Circulation 2001.
6. Egashira K, Koyanagi M, Kitamoto S, et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: Blockade of mcp-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of no synthesis. Faseb J 2000; 14: 1974-78.
7. Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein e-knockout mice. Circulation 2002; 106: 2700-06.
8. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-9.
9. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-15.
10. Mukaida N, Harada A, Matsushima K. Interleukin-8 (il-8) and monocyte chemotactic and activating factor (mcaf/mcp-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998; 9: 9-23.
11. Usui M, Egashira K, Ohtani K, et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. Faseb J 2002; 16: 1838-40.
12. Egashira K, Zhao Q, Kataoka C, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90: 1167-72.
13. Egashira K, Nakano K, Ohtani K, et al. Local delivery of antimonocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol 2007; 27: 2563-8.
14. Kimura S, Egashira K, Nakano K, et al. Local delivery of imatinib mesylate (sti571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 2008; 118: S65-70.
15. Kubo M, Egashira K, Inoue T, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arteriosclerosis, thrombosis, and vascular biology 2009; 29: 796-801.
16. Nakano K, Egashira K, Masuda S, et al. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: Efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv 2009; 2: 277-83.
17. Oda S, Nagahama R, Nakano K, et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg 2010; 52: 412-20.
18. Chen L, Nakano K, Kimura S, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension 2011; 57: 343-50.